Pertuzumab

HER2/neu Receptor Antagonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Pertuzumab is a drug in the HER2/neu Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as HER2/Neu/cerbB2 Antagonists. DrugCentral lists 1 molecular target, including ERBB2. Recorded indications include HER2-positive carcinoma of breast, HER2-positive colon cancer and HER2-positive rectal cancer.

• Drug class: HER2/neu Receptor Antagonist.
• Mechanism of action: HER2/Neu/cerbB2 Antagonists.
• Molecular targets: ERBB2 (1 listed in DrugCentral).
• Indications: HER2-positive carcinoma of breast, HER2-positive colon cancer and HER2-positive rectal cancer.
• ATC code: L01FD02 (HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• HER2-positive carcinoma of breast
• HER2-positive colon cancer
• HER2-positive rectal cancer

Mechanism & targets

• Mechanism of action (MoA): HER2/Neu/cerbB2 Antagonists
• Established pharmacologic class: HER2/neu Receptor Antagonist

Molecular targets (1)

Target	Gene	Action	Activity
Receptor tyrosine-protein kinase erbB-2	ERBB2	other	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2013-06-28	PMDA	—	Chugai Pharmaceutical
2013-03-04	EMA	—	—
2012-06-08	FDA	—	GENENTECH

ATC classification

ATC code	Therapeutic hierarchy
L01FD02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
L01FY01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Combinations of monoclonal antibodies and antibody drug conjugates

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: ERBB2 · Testing Required
• FDA label: ERBB2 · Testing Required
• FDA label: ESR1, ESR2, PGR · Informative PGx
• HCSC label: ERBB2 · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myelosuppression	3372.2
Diarrhoea	2017.1
Ejection fraction decreased	1433.4
Metastases to central nervous system	1311.8
Disease progression	1141.1
Neuropathy peripheral	911.6
Polyneuropathy	775.9
Cardiotoxicity	683.1
Mucosal inflammation	570.0
Neutropenia	534.5
Febrile neutropenia	400.7
No adverse event	382.5

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 380610-27-5
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pertuzumab used for?

DrugCentral lists the following indications for Pertuzumab: HER2-positive carcinoma of breast, HER2-positive colon cancer and HER2-positive rectal cancer.

How does Pertuzumab work?

Pertuzumab is classified as HER2/Neu/cerbB2 Antagonists; its molecular targets in DrugCentral include ERBB2.

When was Pertuzumab first approved?

Pertuzumab was first approved by the FDA in 2012.

What drug class does Pertuzumab belong to?

Pertuzumab is in the HER2/neu Receptor Antagonist class.

Sources

• DrugCentral drug card 4957 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2007641 — compound record and bioactivity
• DrugBank DB06366 — drug record
• FDA UNII K16AIQ8CTM — substance identity
• DailyMed: FDA labels for Pertuzumab — current prescribing information (label search)
• UniProt P04626 (ERBB2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.